When was Emergent BioSolutions founded?

Emergent BioSolutions was founded in 1998 and raised its 1st funding round 10 years after it was founded.

Where is Emergent BioSolutions located?

Emergent BioSolutions is headquartered in Gaithersburg, United States.

Which legal entities is Emergent BioSolutions associated with?

Emergent BioSolutions is associated with Emergent Solutions OÜ and 2 others.

How many employees does Emergent BioSolutions have?

As of Aug 31, 2026, the latest employee count at Emergent BioSolutions is 1366.

Is Emergent BioSolutions a funded company?

Emergent BioSolutions is a funded company, having raised an undisclosed amount across 20 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jun 25, 2008.

When was the latest funding round of Emergent BioSolutions?

Emergent BioSolutions' latest funding was a $***** Grant (prize money) round on Sep 01, 2022, with participation from 1 investor.

What is the annual revenue of Emergent BioSolutions?

Annual revenue of Emergent BioSolutions is between $500M and $1B as on Dec 31, 2025

Where does Emergent BioSolutions rank among its competitors?

Emergent BioSolutions ranks 19th amongst 2696 active competitors, of which 889 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Emergent BioSolutions?

Emergent BioSolutions' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Emergent BioSolutions - 2026 Company Profile, Team, Funding, Competitors & Financials

Emergent BioSolutions is a public company based in Gaithersburg (United States), founded in 1998 by Kevin Miller. It operates as a Developer of vaccines primarily for virus infections. Emergent BioSolutions has raised an undisclosed amount in funding. The company has 2696 active competitors, including 889 funded and 665 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Developer of vaccines primarily for virus infections. The lead candidate NuThrax, a vaccine in combination with a novel immunostimulatory compound CPG 7909 is for anthrax. Also, has PreviThrax, a vaccine in phase 1 trials for anthrax, VAX161C, a recombinant Hemagglutinin influenza subunit antigen - bacterial flagellin fusion protein H5 influenza vaccine for pandemic influenza and UV-4B, and an antiviral iminosugar in phase 1 trials for dengue virus infections. The company also offers CMO services for both bulk drug substances and sterile injectable drug products.

Website: www.emergentbiosolutions.com/
Social
Email ID: *****@ebsi.com

Key Metrics

Founded Year

1998

Location

Gaithersburg, United States

Stage

Public

Latest Funding Round

Grant (prize money), Sep 01, 2022, $*****

Investors

Advent Life Sciences & 13 more

Ranked

19^th among 2696 active competitors

Annual Revenue

$500M - $1B as on Dec 31, 2025

Employee Count

1,366 as on Aug 31, 2026

Investment & Acquisitions

Swiss Rockets & 6 more

Similar Companies

Moderna & 387 more

Exit Details

Public

View Emergent BioSolutions' full profile

Emergent BioSolutions is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Emergent Solutions OÜ CIN: 16253683 , Estonia, Active	Jun 15, 2021	€0 - €1M (As on Dec 31, 2023)	1 (As on Sep 30, 2024)
EMERGENT BIOSOLUTIONS INC. CIN: 1367644 , United States, Active	Aug 13, 2006	$500M - $1B (As on Dec 31, 2025)	-	-
EMERGENT BIOSOLUTIONS INC CIN: 14-1902018 , United States, Active	Dec 18, 2003	-	1600 (As on Dec 31, 2023)	-

Emergent BioSolutions got listed on Nov 17, 2006.

Click here to take a look at Emergent BioSolutions's IPO in detail

Emergent BioSolutions has raised funding over 20 rounds. Its first funding round was on Jun 25, 2008. Its latest funding round was a Grant (prize money) round on Sep 01, 2022 for $*****. 1 investor participated in its latest round. Emergent BioSolutions has 14 institutional investors.

Here is the list of recent funding rounds of Emergent BioSolutions:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 01, 2022	6017018	Grant (prize money)	6784701	2524882	1194583	4660615
Apr 03, 2020	2249187	Grant (prize money)	5865938	8512282	4585090	Public Health Emergency
Feb 19, 2020	3814429	Post IPO	3403687	1485700	8457090	Aigen Investment Management

Access funding benchmarks and valuations. Sign up today!

View details of Emergent BioSolutions's funding rounds and investors

The founders of Emergent BioSolutions is Kevin Miller.

Here are the details of Emergent BioSolutions' key team members:

Kevin Miller: Co-Founder of Emergent BioSolutions.

View details of Emergent BioSolutions's Founder profiles and Board Members

Emergent BioSolutions' employee count trend

Emergent BioSolutions has 1,366 employees as of Aug 26. Here is Emergent BioSolutions's employee count trend over the years:

Employee count trend for Emergent BioSolutions

Uncover Emergent BioSolutions' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Emergent BioSolutions include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Emergent BioSolutions, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, Khosla Ventures & 23 others	72/100
8th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
19th	Emergent BioSolutions 1998, Gaithersburg (United States), Public	Developer of vaccines primarily for virus infections	-	Advent Life Sciences, Orbimed & 12 others	67/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Emergent BioSolutions's competitors? Click here to see the top ones

Emergent BioSolutions has made 2 investments in companies including Swiss Rockets and Aptevo Therapeutics. Emergent BioSolutions has also acquired 5 companies including TEMBEXA and ADAPT Pharma.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Mar 14, 2025	Investments	Swiss Rockets	2018	Basel (Switzerland)
Sep 27, 2022	Acquisition	TEMBEXA		-
Aug 28, 2018	Acquisition	ADAPT Pharma	2014	Dublin (Ireland)

Want to know more about where corporates are investing? Sign up today!

See all acquisitions by Emergent BioSolutions

Here is the latest report on Emergent BioSolutions's sector:

Free

Infectious Diseases - Sector Report

Edition: August, 2026 (69 Pages)

View all reports related to Emergent BioSolutions

Media has covered Emergent BioSolutions for a total of 30 events in the last 1 year, 10 of them have been about company updates and 3 about partnerships.